Bellerophon Therapeutics names COO
This article was originally published in Scrip
Bellerophon Therapeutics, a clinical-stage biotherapeutics company, has appointed Amit Agrawal chief operating officer, effective 8 July, and Dr Naseem Amin an independent director of the company, effective 29 June. Mr Agrawal joins Bellerophon from Amgen, where, since 2012, he was director of strategy and corporate development. While at Amgen, Mr Agrawal worked across several areas of the business covering R&D, manufacturing operations, commercial planning and business development. Meanwhile, Dr Amin, who was also appointed to Bellerophon's audit committee, has broad industry experience in the biotech and medical device industries. Until 2014, he was chief scientific officer of Smith and Nephew, where he provided scientific leadership to the organization.
You may also be interested in...
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.
A selection of features you might have missed from the first six months of 2020, covering key topics from COVID-19 strategies in medtech to an analysis of pipeline focus areas across the pharma sector. Click on each section to get the full story behind the data.
The two-part vaccine becomes the second against Ebola to get approval. Janssen is now collaborating with the World Health Organization on vaccine pre-qualification to get it to people in need.